The DOI matches its Crossref record; 203 of the 203 references it cites were found in a registry or an index.
Role of interleukin-6 in cancer progression and therapeutic resistance
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Veuger, S. J., Hunter, J. E., & Durkacz, B. W. (2008) · Oncogene · doi:10.1038/onc.2008.439 · Cited by 135
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“Enhanced aerobic glycolysis is one of the prominent phenotypes of a majority of cancer cells which facilitate proliferation and confer protection against death, besides energy production [122, 123].”
BackgroundImmunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196 · cited 1×
“known as the epithelial-to-mesenchymal transition (EMT) and its counterpart, the mesenchymal-to-epithelial transition [139].”
BackgroundPatterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Oxidative stress, inflammation, and cancer: How are they linked?
Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.09.006 · Cited by 5,441
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212 · cited 3×
“It has a characteristic structure made up of four long α-helices arranged in an up–up–down–down topology [21].”
BackgroundInfluentialCancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Colotta, F., Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp127 · Cited by 2,890
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
Rodier, F., Coppé, J.-P., Patil, C. K., Hoeijmakers, W. A. M., Muñoz, D. P., Raza, S. R., Freund, A., Campeau, E., Davalos, A. R., & Campisi, J. (2009) · Nature Cell Biology · doi:10.1038/ncb1909 · Cited by 2,232
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Chronic inflammation and cytokines in the tumor microenvironment
Landskron, G., De la Fuente, M., Thuwajit, P., Thuwajit, C., & Hermoso, M. A. (2014) · Journal of Immunology Research · doi:10.1155/2014/149185 · Cited by 1,765
Xing, Z., Gauldie, J., Cox, G., Baumann, H., Jordana, M., Lei, X. F., & Achong, M. K. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1368 · Cited by 1,498
Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
Gupta, P. B., Fillmore, C. M., Jiang, G., Shapira, S. D., Tao, K., Kuperwasser, C., & Lander, E. S. (2011) · Cell · doi:10.1016/j.cell.2011.07.026 · Cited by 1,475
gp 130 AND THE INTERLEUKIN-6 FAMILY OF CYTOKINES
Taga, T., & Kishimoto, T. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.797 · Cited by 1,461
Iliopoulos, D., Hirsch, H. A., & Struhl, K. (2009) · Cell · doi:10.1016/j.cell.2009.10.014 · Cited by 1,374
Atreya, R., Mudter, J., Finotto, S., Müllberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., et al. (2000) · Nature Medicine · doi:10.1038/75068 · Cited by 1,293
Interleukin-6 family of cytokines and gp130
Kishimoto, T., Akira, S., Narazaki, M., & Taga, T. (1995) · Blood · doi:10.1182/blood.v86.4.1243.bloodjournal8641243 · Cited by 1,272
Giacinti, C., & Giordano, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209615 · Cited by 1,216
Hirano, T., Ishihara, K., & Hibi, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203551 · Cited by 1,190
Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer
Grivennikov, S. I., & Karin, M. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.005 · Cited by 1,160
Stattic: a small-molecule inhibitor of STAT3 activation and dimerization
Schust, J., Sperl, B., Hollis, A., Mayer, T. U., & Berg, T. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.09.018 · Cited by 1,105
Acute phase reaction and acute phase proteins
Gruys, E., Toussaint, M. J. M., Niewold, T. A., & Koopmans, S. J. (2005) · Journal of Zhejiang University-SCIENCE B · doi:10.1631/jzus.2005.b1045 · Cited by 1,080
Rose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040 · cited 2×
“Like sIL-6R, a soluble form of the signal transducer protein gp130 (sgp130) is also present in the circulation at relatively high concentrations during inflammation and cancer [37, 39].”
BackgroundMolecular cloning and expression of an IL-6 signal transducer, gp130
Hibi, M., Murakami, M., Saito, M., Hirano, T., Taga, T., & Kishimoto, T. (1990) · Cell · doi:10.1016/0092-8674(90)90411-7 · Cited by 1,039
Mitchem, J. B., Brennan, D. J., Knolhoff, B. L., Belt, B. A., Zhu, Y., Sanford, D. E., Belaygorod, L., Carpenter, D., Collins, L., Piwnica-Worms, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2731 · Cited by 943
Nevins, J. R. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.699 · Cited by 922
Carey, A. L., Steinberg, G. R., Macaulay, S. L., Thomas, W. G., Holmes, A. G., Ramm, G., Prelovsek, O., Hohnen-Behrens, C., Watt, M. J., James, D. E., et al. (2006) · Diabetes · doi:10.2337/db05-1404 · Cited by 898
IL-6/IL-6 receptor system and its role in physiological and pathological conditions
Mihara, M., Hashizume, M., Yoshida, H., Suzuki, M., & Shiina, M. (2012) · Clinical Science · doi:10.1042/cs20110340 · Cited by 895
SOCS3 negatively regulates IL-6 signaling in vivo
Croker, B. A., Krebs, D. L., Zhang, J.-G., Wormald, S., Willson, T. A., Stanley, E. G., Robb, L., Greenhalgh, C. J., Förster, I., Clausen, B. E., et al. (2003) · Nature Immunology · doi:10.1038/ni931 · Cited by 840
Tilg, H., Trehu, E., Atkins, M., Dinarello, C., & Mier, J. (1994) · Blood · doi:10.1182/blood.v83.1.113.113 · Cited by 817
Sansone, P., Storci, G., Tavolari, S., Guarnieri, T., Giovannini, C., Taffurelli, M., Ceccarelli, C., Santini, D., Paterini, P., Marcu, K. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32533 · Cited by 779
Interleukin‐6 myokine signaling in skeletal muscle: a double‐edged sword?
Muñoz‐Cánoves, P., Scheele, C., Pedersen, B. K., & Serrano, A. L. (2013) · The FEBS Journal · doi:10.1111/febs.12338 · Cited by 774
New horizons in tumor microenvironment biology: challenges and opportunities
Chen, F., Zhuang, X., Lin, L., Yu, P., Wang, Y., Shi, Y., Hu, G., & Sun, Y. (2015) · BMC Medicine · doi:10.1186/s12916-015-0278-7 · Cited by 704 · cited 1×
“therapeutic gain and tumour-free survival [163].”
The two faces of IL-6 in the tumor microenvironment
Fisher, D. T., Appenheimer, M. M., & Evans, S. S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.008 · Cited by 693
Interleukin-6 signaling pathway in targeted therapy for cancer
Guo, Y., Xu, F., Lu, T., Duan, Z., & Zhang, Z. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.04.007 · Cited by 686
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Jones, S. A., Scheller, J., & Rose-John, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57158 · Cited by 683
Hirano, T., Taga, T., Nakano, N., Yasukawa, K., Kashiwamura, S., Shimizu, K., Nakajima, K., Pyun, K. H., & Kishimoto, T. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.16.5490 · Cited by 677
Blaskovich, M. A., Sun, J., Cantor, A. B., Turkson, J., Jove, R., & Sebti, S. M. (2003) · PubMed · Cited by 643
Soluble gp130 is the natural inhibitor of soluble interleukin‐6 receptor transsignaling responses
Jostock, T., Müllberg, J., Özbek, S., Atreya, R., Blinn, G., Voltz, N., Fischer, M., Neurath, M. F., & Rose‐John, S. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.01867.x · Cited by 641
Helbig, G., Christopherson, K. W., Bhat-Nakshatri, P., Kumar, S., Kishimoto, H., Miller, K. D., Broxmeyer, H. E., & Nakshatri, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300609200 · Cited by 639
p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation
Kawauchi, K., Araki, K., Tobiume, K., & Tanaka, N. (2008) · Nature Cell Biology · doi:10.1038/ncb1724 · Cited by 637
NF-κB and cancer — identifying targets and mechanisms
Naugler, W. E., & Karin, M. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.01.020 · Cited by 636
Yoshida, K., Taga, T., Saito, M., Suematsu, S., Kumanogoh, A., Tanaka, T., Fujiwara, H., Hirata, M., Yamagami, T., Nakahata, T., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.407 · Cited by 635
Bastard, J.-P., Maachi, M., van Nhieu, J. T., Jardel, C., Bruckert, E., Grimaldi, A., Robert, J.-J., Capeau, J., & Hainque, B. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8450 · Cited by 625
The soluble interleukin 6 receptor: mechanisms of production and implications in disease
JONES, S. A., HORIUCHI, S., TOPLEY, N., YAMAMOTO, N., & FULLER, G. M. (2001) · The FASEB Journal · doi:10.1096/fj.99-1003rev · Cited by 623
Interleukin-6 and its receptors: a highly regulated and dynamic system
Wolf, J., Rose-John, S., & Garbers, C. (2014) · Cytokine · doi:10.1016/j.cyto.2014.05.024 · Cited by 618
Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice
Kujawski, M., Kortylewski, M., Lee, H., Herrmann, A., Kay, H., & Yu, H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35213 · Cited by 581
Aderka, D., Le, J., & Vilček, J. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.11.3517 · Cited by 574
Gritsko, T., Williams, A., Turkson, J., Kaneko, S., Bowman, T., Huang, M., Nam, S., Eweis, I., Diaz, N., Sullivan, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1752 · Cited by 563
Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage
Grivennikov, S. I., & Karin, M. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.140145 · Cited by 560 · cited 1×
“Amongst these, IL-6 is important in the development of human cancer and activates oncogenic pathways, and it is known to be deregulated in cancer [77].”
BackgroundInflammation and Cancer: IL-6 and STAT3 Complete the Link
Bromberg, J., & Wang, T. C. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.009 · Cited by 542
Korkaya, H., Kim, G.-I., Davis, A., Malik, F., Henry, N. L., Ithimakin, S., Quraishi, A. A., Tawakkol, N., D'Angelo, R., Paulson, A. K., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.06.014 · Cited by 538
Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway
Wei, L.-H., Kuo, M.-L., Chen, C.-A., Chou, C.-H., Lai, K.-B., Lee, C.-N., & Hsieh, C.-Y. (2003) · Oncogene · doi:10.1038/sj.onc.1206226 · Cited by 536
Trikha, M., Corringham, R. E., Klein, B., & Rossi, J. (2003) · PubMed · Cited by 506
Song, H., Wang, R., Wang, S., & Lin, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409894102 · Cited by 504
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma
Hideshima, T., Nakamura, N., Chauhan, D., & Anderson, K. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204833 · Cited by 478 · cited 1×
“For example, IL-6 confers protection from dexamethasone-induced apoptosis by activating PI3K/AKT signalling and inactivating casapase-9, thereby inhibiting apoptosis in multiple myeloma cells [109].”
BackgroundSteensberg, A., Febbraio, M. A., Osada, T., Schjerling, P., van Hall, G., Saltin, B., & Pedersen, B. K. (2001) · The Journal of Physiology · doi:10.1111/j.1469-7793.2001.00633.x · Cited by 443
DNA Damage-Mediated Induction of a Chemoresistant Niche
Gilbert, L. A., & Hemann, M. T. (2010) · Cell · doi:10.1016/j.cell.2010.09.043 · Cited by 428 · cited 1×
“IL-6 secreted by tumour-associated endothelial cells in the tumour microenvironment has been suggested to protect lymphoma cells from genotoxic chemotherapy [149], whilst per-”
BackgroundInterleukin-6 - A Key Regulator of Colorectal Cancer Development
Waldner, M. J., Foersch, S., & Neurath, M. F. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4614 · Cited by 418
Targeting STAT3 in cancer: how successful are we?
Yue, P., & Turkson, J. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802565791 · Cited by 413
IL-6 and NF-IL6 in acute-phase response and viral infection
Akira, S., & Kishimoto†, T. (1992) · Immunological Reviews · doi:10.1111/j.1600-065x.1992.tb01407.x · Cited by 411
NF-κB as a primary regulator of the stress response
Mercurio, F., & Manning, A. M. (1999) · Oncogene · doi:10.1038/sj.onc.1203174 · Cited by 411
Versatile functions for IL-6 in metabolism and cancer
Mauer, J., Denson, J. L., & Brüning, J. C. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.12.008 · Cited by 407
Activation of Interleukin-6 Gene Expression through the NF-κB Transcription Factor
Libermann, T. A., & Baltimore, D. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.5.2327-2334.1990 · Cited by 403
Role of Stat3 in Regulating p53 Expression and Function
Niu, G., Wright, K. L., Ma, Y., Wright, G. M., Huang, M., Irby, R., Briggs, J., Karras, J., Cress, W. D., Pardoll, D., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7432-7440.2005 · Cited by 392
Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
Coward, J., Kulbe, H., Chakravarty, P., Leader, D., Vassileva, V., Leinster, D. A., Thompson, R., Schioppa, T., Nemeth, J., Vermeulen, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0945 · Cited by 390
Nagasaki, T., Hara, M., Nakanishi, H., Takahashi, H., Sato, M., & Takeyama, H. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.748 · Cited by 385
Autocrine IL-6 Signaling: A Key Event in Tumorigenesis?
Grivennikov, S., & Karin, M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.020 · Cited by 368
The role of intratumoral and systemic IL-6 in breast cancer
Dethlefsen, C., Højfeldt, G., & Hojman, P. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2488-z · Cited by 363
Bak regulates mitochondrial morphology and pathology during apoptosis by interacting with mitofusins
Brooks, C., Wei, Q., Feng, L., Dong, G., Tao, Y., Mei, L., Xie, Z.-J., & Dong, Z. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703976104 · Cited by 351
p38 MAPK and NF-κB Collaborate to Induce Interleukin-6 Gene Expression and Release
Craig, R., Larkin, A., Mingo, A. M., Thuerauf, D. J., Andrews, C., McDonough, P. M., & Glembotski, C. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909695199 · Cited by 339
Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells.
Conze, D. B., Weiss, L., Regen, P. S., Bhushan, A., Weaver, D. L., Johnson, P. F., & Rincón, M. (2001) · PubMed · Cited by 334
IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation
McLoughlin, R. M., Jenkins, B. J., Grail, D., Williams, A. S., Fielding, C. A., Parker, C. R., Ernst, M., Topley, N., & Jones, S. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501794102 · Cited by 333
Maintenance of Pluripotency in Human Embryonic Stem Cells Is STAT3 Independent
Humphrey, R. K., Beattie, G. M., Lopez, A. D., Bucay, N., King, C. C., Firpo, M. T., Rose‐John, S., & Hayek, A. (2004) · STEM CELLS · doi:10.1634/stemcells.22-4-522 · Cited by 319
Valencia, T., Kim, J. Y., Abu-Baker, S., Moscat-Pardos, J., Ahn, C. S., Reina-Campos, M., Duran, A., Castilla, E. A., Metallo, C. M., Diaz-Meco, M. T., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.004 · Cited by 304
Kim, S.-Y., Kang, J. W., Song, X., Kim, B. K., Yoo, Y. D., Kwon, Y. T., & Lee, Y. J. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.01.007 · Cited by 297
The soluble Interleukin 6 receptor: Generation and role in inflammation and cancer
Chalaris, A., Garbers, C., Rabe, B., Rose-John, S., & Scheller, J. (2011) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2010.10.007 · Cited by 289
Elevation of circulating interleukin 6 after surgery: Factors influencing the serum level
Sakamoto, K., Arakawa, H., Mita, S., Ishiko, T., Ikei, S., Egami, H., Hisano, S., & Ogawa, M. (1994) · Cytokine · doi:10.1016/1043-4666(94)90040-x · Cited by 286
Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention
Xiong, A., Yang, Z., Shen, Y., Zhou, J., & Shen, Q. (2014) · Cancers · doi:10.3390/cancers6020926 · Cited by 283
Differences in Wound Healing in Mice with Deficiency of IL-6 versus IL-6 Receptor
McFarland-Mancini, M. M., Funk, H. M., Paluch, A. M., Zhou, M., Giridhar, P. V., Mercer, C. A., Kozma, S. C., & Drew, A. F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901929 · Cited by 249
IL-6 Induces NF-κB Activation in the Intestinal Epithelia
Wang, L., Walia, B., Evans, J., Gewirtz, A. T., Merlin, D., & Sitaraman, S. V. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.6.3194 · Cited by 243
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
Kontzias, A., Kotlyar, A., Laurence, A., Changelian, P., & O'Shea, J. J. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.06.008 · Cited by 233
Wunderlich, F. T., Ströhle, P., Könner, A. C., Gruber, S., Tovar, S., Brönneke, H. S., Juntti-Berggren, L., Li, L.-S., van Rooijen, N., Libert, C., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.06.011 · Cited by 229 · cited 1×
“For example, in the absence of IL-6, mice develop glucose intolerance and insulin resistance, whilst IL6 mice exhibit signs of liver inflammation [25].”
BackgroundIsomoto, H., Kobayashi, S., Werneburg, N. W., Bronk, S. F., Guicciardi, M. E., Frank, D. A., & Gores, G. J. (2005) · Hepatology · doi:10.1002/hep.20966 · Cited by 227
Interleukin 6 Supports the Maintenance of p53 Tumor Suppressor Gene Promoter Methylation
Hodge, D. R., Peng, B., Cherry, J. C., Hurt, E. M., Fox, S. D., Kelley, J. A., Munroe, D. J., & Farrar, W. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3589 · Cited by 226
Hypermethylation of tumor suppressor genes in cancer
Herman, J. G. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1999.0138 · Cited by 218
Wu, Z.-H., Wong, E. T., Shi, Y., Niu, J., Chen, Z., Miyamoto, S., & Tergaonkar, V. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.010 · Cited by 207
Yawata, H., Yasukawa, K., Natsuka, S., Murakami, M., Yamasaki, K., Hibi, M., Taga, T., & Kishimoto, T. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05815.x · Cited by 204
Zhuang, L., Lee, C. S., Scolyer, R. A., McCarthy, S. W., Zhang, X. D., Thompson, J. F., & Hersey, P. (2007) · Modern Pathology · doi:10.1038/modpathol.3800750 · Cited by 202
Hyperglycemia Induces Monocytic Release of Interleukin-6 via Induction of Protein Kinase C-α and -β
Devaraj, S., Venugopal, S. K., Singh, U., & Jialal, I. (2005) · Diabetes · doi:10.2337/diabetes.54.1.85 · Cited by 202
Eghtedar, A., Verstovsek, S., Estrov, Z., Burger, J., Cortes, J., Bivins, C., Faderl, S., Ferrajoli, A., Borthakur, G., George, S., et al. (2012) · Blood · doi:10.1182/blood-2011-12-400051 · Cited by 200
LPS and TNFα induce SOCS3 mRNA and inhibit IL‐6‐induced activation of STAT3 in macrophages
Bode, J. G., Nimmesgern, A., Schmitz, J., Schaper, F., Schmitt, M., Frisch, W., Häussinger, D., Heinrich, P. C., & Graeve, L. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01662-2 · Cited by 196
Patchen, M., MacVittie, T., Williams, J., Schwartz, G., & Souza, L. (1991) · Blood · doi:10.1182/blood.v77.3.472.472 · Cited by 191
Chang, C. H., Hsiao, C. F., Yeh, Y. M., Chang, G. C., Tsai, Y. H., Chen, Y. M., Huang, M. S., Chen, H. L., Li, Y. J., Yang, P. C., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.27892 · Cited by 189
Ricciardi, M., Zanotto, M., Malpeli, G., Bassi, G., Perbellini, O., Chilosi, M., Bifari, F., & Krampera, M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.29 · Cited by 182
Wegiel, B., Bjartell, A., Culig, Z., & Persson, J. L. (2008) · International Journal of Cancer · doi:10.1002/ijc.23261 · Cited by 179
Interleukin‐6 promotes tumorigenesis by altering DNA methylation in oral cancer cells
Gasche, J. A., Hoffmann, J., Boland, C. R., & Goel, A. (2011) · International Journal of Cancer · doi:10.1002/ijc.25764 · Cited by 178
Tormo, D., Chęcińska, A., Alonso-Curbelo, D., Pérez-Guijarro, E., Cañón, E., Riveiro-Falkenbach, E., Calvo, T. G., Larribere, L., Megías, D., Mulero, F., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.07.004 · Cited by 178
Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK
White, J. P., Puppa, M. J., Gao, S., Sato, S., Welle, S. L., & Carson, J. A. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00410.2012 · Cited by 178
Houde, C., Li, Y., Song, L., Barton, K., Zhang, Q., Godwin, J., Nand, S., Toor, A., Alkan, S., Smadja, N. V., et al. (2004) · Blood · doi:10.1182/blood-2003-12-4114 · Cited by 177
Jorcyk, C. L., Tawara, K., & Jorcyk, C. L. (2011) · Cancer Management and Research · doi:10.2147/cmr.s18101 · Cited by 176
Wei, L.-H., Kuo, M.-L., Chen, C.-A., Chou, C.-H., Cheng, W.-F., Chang, M.-C., Su, J.-L., & Hsieh, C.-Y. (2001) · Oncogene · doi:10.1038/sj.onc.1204733 · Cited by 174
Interleukin-6 and Neural Stem Cells: More Than Gliogenesis
Islam, O., Gong, X., Rose-John, S., & Heese, K. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-05-0463 · Cited by 172
Oh, K., Lee, O.-Y., Shon, S.-Y., Nam, O., Ryu, P. M., Seo, M. W., & Lee, D. (2013) · Breast Cancer Research · doi:10.1186/bcr3473 · Cited by 171
Borsellino, N., Belldegrun, A. S., & Bonavida, B. (1995) · PubMed · Cited by 171
Interleukin-6: A multifunctional targetable cytokine in human prostate cancer
Culig, Z., & Puhr, M. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.05.033 · Cited by 170
A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells
Jourdan, M., Veyrune, J., Vos, J. D., Redal, N., Couderc, G., & Klein, B. (2003) · Oncogene · doi:10.1038/sj.onc.1206423 · Cited by 170
Barkhausen, T., Tschernig, T., Rosenstiel, P., van Griensven, M., Vonberg, R.-P., Dorsch, M., Mueller-Heine, A., Chalaris, A., Scheller, J., Rose-John, S., et al. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318211ff56 · Cited by 169
Liu, C., Lin, J., Hsu, T., Su, K., Li, A. F., Hsu, H., & Hung, S. (2015) · International Journal of Cancer · doi:10.1002/ijc.29033 · Cited by 169
Leu, C.-M., Wong, F.-H., Chang, C., Huang, S.-F., & Hu, C.-P. (2003) · Oncogene · doi:10.1038/sj.onc.1207084 · Cited by 168
Shinriki, S., Jono, H., Ota, K., Ueda, M., Kudo, M., Ota, T., Oike, Y., Endo, M., Ibusuki, M., Hiraki, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0287 · Cited by 163
Postprandial Variations of Plasma Inflammatory Markers in Abdominally Obese Men
Blackburn, P., Després, J., Lamarche, B., Tremblay, A., Bergeron, J., Lemieux, I., & Couillard, C. (2006) · Obesity · doi:10.1038/oby.2006.201 · Cited by 157
Cancer-associated adipocytes promotes breast tumor radioresistance
Bochet, L., Meulle, A., Imbert, S., Salles, B., Valet, P., & Muller, C. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.06.101 · Cited by 153
Anti‐interleukin‐6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases
Tanaka, T., Narazaki, M., & Kishimoto, T. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.03.023 · Cited by 153
Wei, Q., Guo, P., Mu, K., Zhang, Y., Zhao, W., Huai, W., Qiu, Y., Li, T., Ma, X., Liu, Y., et al. (2015) · Laboratory Investigation · doi:10.1038/labinvest.2015.63 · Cited by 152
Targeting inflammatory pathways for tumor radiosensitization
Deorukhkar, A., & Krishnan, S. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.06.039 · Cited by 151
IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus
Chen, M., Chen, P.-T., Lu, M. S., Lin, P. Y., Chen, W., & Lee, K. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-26 · Cited by 151
NF-κB and STAT3 cooperatively induce IL6 in starved cancer cells
Yoon, S., Woo, S., Kang, J.-H., Kim, K., Hj, S., Gwak, H.-S., Park, S., & Chwae, Y.-J. (2011) · Oncogene · doi:10.1038/onc.2011.517 · Cited by 147
CYCLIC PLASMA IL-6 LEVELS DURING NORMAL MENSTRUAL CYCLE
Angstwurm, M., Gärtner, R., & Ziegler‐Heitbrock, H. W. L. (1997) · Cytokine · doi:10.1006/cyto.1996.0178 · Cited by 147
Kesanakurti, D., Chetty, C., Maddirela, D. R., Gujrati, M., & Rao, J. (2012) · Oncogene · doi:10.1038/onc.2012.546 · Cited by 146
The role of IL-6 in the radiation response of prostate cancer
Wu, C., Chen, M., Chen, W., & Hsieh, C. (2013) · Radiation Oncology · doi:10.1186/1748-717x-8-159 · Cited by 144
Lederle, W., Depner, S., Schnur, S., Obermueller, E., Catone, N., Just, A., Fusenig, N. E., & Mueller, M. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25621 · Cited by 143
Xu, H., Wei, L., Zhang, Y., Liu, L., Luo, X., Zeng, Y., Wu, H., Lan, Q., & Chu, Z. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-330 · Cited by 140
Interleukin‐6: Possible biological roles during exercise
Reihmane, D., & Dela, F. (2013) · European Journal of Sport Science · doi:10.1080/17461391.2013.776640 · Cited by 137
Jing, N., Li, Y., Xiong, W., Sha, W., Jing, L., & Tweardy, D. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-4041 · Cited by 134
Tocilizumab, a Proposed Therapy for the Cachexia of Interleukin6-Expressing Lung Cancer
Ando, K., Takahashi, F., Kato, M., Kaneko, N., Doi, T., Ohe, Y., Koizumi, F., Nishio, K., & Takahashi, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102436 · Cited by 133
IL-6 Expression Regulates Tumorigenicity and Correlates with Prognosis in Bladder Cancer
Chen, M., Lin, P., Wu, C., Chen, W., & Wu, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061901 · Cited by 132
IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma
Cozen, W., Gill, P. S., Ingles, S. A., Masood, R., nez-Maza, O. M. I., Cockburn, M., Gauderman, W. J., Pike, M. C., Bernstein, L., Nathwani, B. N., et al. (2004) · Blood · doi:10.1182/blood-2003-08-2860 · Cited by 131
Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer.
Johnson, C. N., Han, Y., Hughart, N., McCarra, J., Alpini, G. D., & Meng, F. (2012) · PubMed · doi:10.3978/j.issn.2224-4778.2011.11.02 · Cited by 130
Transient elevation of glycolysis confers radio-resistance by facilitating DNA repair in cells
Bhatt, A. N., Chauhan, A., Khanna, S., Rai, Y., Singh, S. P., Soni, R., Kalra, N., & Dwarakanath, B. S. R. (2015) · BMC Cancer · doi:10.1186/s12885-015-1368-9 · Cited by 124
Self-citationAndo, M., Uehara, I., Kogure, K., Asano, Y., Nakajima, W., Abe, Y., Kawauchi, K., & Tanaka, N. (2010) · Journal of Nippon Medical School · doi:10.1272/jnms.77.97 · Cited by 122
Émilie, D., Wijdenes, J., Gisselbrecht, C., Jarrousse, B., Billaud, É., Blay, J., Gabarre, J., Gaillard, J., Brochier, J., & Raphaël, M. (1994) · Blood · doi:10.1182/blood.v84.8.2472.2472 · Cited by 122
Yang, F., Brown, C. E., Buettner, R., Hedvat, M., Starr, R., Scuto, A., Schroeder, A., Jensen, M. C., & Jove, R. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0947 · Cited by 121
Hodge, D. R., Cho, E., Copeland, T. D., Guszczynski, T., Yang, E., Seth, A. K., & Farrar, W. L. (2007) · PubMed · Cited by 121
Shibayama, O., Yoshiuchi, K., Inagaki, M., Matsuoka, Y., Yoshikawa, E., Sugawara, Y., Akechi, T., Wada, N., Imoto, S., Murakami, K., et al. (2014) · Cancer Medicine · doi:10.1002/cam4.174 · Cited by 120
Curnow, J., Scheel‐Toellner, D., Jenkinson, W. E., Raza, K., Durrani, O. M., Faint, J., Rauz, S., Wloka, K., Pilling, D., Rose‐John, S., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.5290 · Cited by 119
Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
Hart, S., Goh, K. C., Novotny‐Diermayr, V., Tan, Y., Madan, B., Amalini, C., Ong, L. C., Kheng, B., Cheong, A., Zhou, J., et al. (2011) · Blood Cancer Journal · doi:10.1038/bcj.2011.43 · Cited by 118
Karkera, J. D., Steiner, H., Li, W., Skradski, V., Moser, P. L., Riethdorf, S., Reddy, M. P., Puchalski, T. A., Safer, K., Prabhakar, U., et al. (2011) · The Prostate · doi:10.1002/pros.21362 · Cited by 118
Characterization of Patients With Advanced Pancreatic Cancer and High Serum Interleukin-6 Levels
Miura, T., Mitsunaga, S., Ikeda, M., Shimizu, S., Ohno, I., Takahashi, H., Furuse, J., Inagaki, M., Higashi, S., Kato, H., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000335 · Cited by 109
Radtke, S., Wüller, S., Yang, X., Lippok, B. E., Mütze, B., Mais, C., de Leur, H. S.-V., Bode, J. G., Gaestel, M., Heinrich, P. C., et al. (2010) · Journal of Cell Science · doi:10.1242/jcs.065326 · Cited by 107
Lin, M., Juan, C.-Y., Chang, K., Chen, W., & Kuo, M. (2001) · Carcinogenesis · doi:10.1093/carcin/22.12.1947 · Cited by 107
Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein
Urashima, M., Ogata, A., Chauhan, D., Vídriales, M., Teoh, G., Hoshi, Y., Schlossman, R., DeCaprio, J. A., & Anderson, K. C. (1996) · Blood · doi:10.1182/blood.v88.6.2219.bloodjournal8862219 · Cited by 107
Song, L., Smith, M. A., Doshi, P. D., Sasser, K., Fulp, W. J., Altiok, S., & Haura, E. B. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000193 · Cited by 104
Huang, C., Yang, G., Jiang, T., Huang, K., Cao, J., & Qiu, Z. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-51 · Cited by 103
Yeoh, G. C., Ernst, M., Rose‐John, S., Akhurst, B., Payne, C. J., Long, S., Alexander, W. S., Croker, B. A., Grail, D., & Matthews, V. B. (2007) · Hepatology · doi:10.1002/hep.21535 · Cited by 103
Schiechl, G., Bauer, B., Fuss, I. J., Lang, S. A., Moser, C., Ruemmele, P., Rose‐John, S., Neurath, M. F., Geissler, E. K., Schlitt, H. J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42540 · Cited by 102
Patel, S. A., Bhambra, U., Charalambous, M. P., David, R. M., Edwards, R. J., Lightfoot, T., Boobis, A. R., & Gooderham, N. J. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.540 · Cited by 100
Waxman, A. B., & Kolliputi, N. (2009) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2008-0302oc · Cited by 98
Inhibition of the JAK2/STAT3 Pathway Reduces Gastric Cancer Growth In Vitro and In Vivo
Judd, L. M., Menheniott, T. R., Ling, H. Y., Jackson, C. B., Howlett, M., Kalantzis, A., Priebe, W., & Giraud, A. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095993 · Cited by 97
Chen, C., Loy, A., Cen, L., Chan, C., Hsieh, F.-C., Cheng, G., Wu, B., Qualman, S. J., Kunisada, K., Yamauchi‐Takihara, K., et al. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-111 · Cited by 94
Jing, N., Zhu, Q., Yuan, P., Li, Y., Mao, L., & Tweardy, D. J. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0302 · Cited by 94
Moreau, P., Harousseau, J., Wijdenes, J., Morineau, N., Milpied, N. J., & Bataille, R. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02093.x · Cited by 89
Inhibition of interleukin‐6 signaling by galiellalactone
Weidler, M., Rether, J., Anke, T., & Erkel, G. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02115-3 · Cited by 88
Isobe, A., Sawada, K., Kinose, Y., Ohyagi-Hara, C., Nakatsuka, E., Makino, H., Ogura, T., Mizuno, T., Suzuki, N., Morii, E., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118080 · Cited by 87
Adverse Events of Monoclonal Antibodies Used for Cancer Therapy
Guan, M., Zhou, Y., Sun, J., & Chen, S.-C. (2015) · BioMed Research International · doi:10.1155/2015/428169 · Cited by 86
p38α Stabilizes Interleukin-6 mRNA via Multiple AU-richElements
Zhao, W., Liu, M., & Kirkwood, K. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m707573200 · Cited by 85
Shi, X., Franko, B., Frantz, C., Amin, H. M., & Lai, R. L. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06259.x · Cited by 84
Su, Y., Li, G., Zhang, X., Gu, J., Zhang, C., Tian, Z., & Zhang, J. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.8.6263 · Cited by 83
Kratsovnik, E., Bromberg, Y., Sperling, O., & Zoref‐Shani, E. (2005) · Journal of Molecular Neuroscience · doi:10.1385/jmn:26:1:027 · Cited by 81
Macciò, A., & Madeddu, C. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1080-7 · Cited by 80
García‐Tuñón, I., Ricote, M., Ruiz, A., Fraile, B., Paniagua, R., & Royuela, M. (2005) · Histopathology · doi:10.1111/j.1365-2559.2005.02178.x · Cited by 76
Touboul, C., Lis, R., Al Farsi, H., Raynaud, C. M., Warfa, M., Althawadi, H., Mery, E., Mirshahi, M., & Rafii, A. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-28 · Cited by 75 · cited 1×
“Cancer-associated adipocytes can also promote radio-resistance by secreting IL-6 [158], whilst IL-6 and IL8 secreted by mesenchymal stem cells activate macrophages in the microenvironment of human colorectal and ovarian cancers, causing chemoresistance [159, 160].”
Zou, M., Zhang, X., & Xu, C. (2015) · Cellular Oncology · doi:10.1007/s13402-015-0251-7 · Cited by 72
SD-1029 Inhibits Signal Transducer and Activator of Transcription 3 Nuclear Translocation
Duan, Z., Bradner, J. E., Greenberg, E. F., Levine, R. L., Foster, R., Mahoney, J., & Seiden, M. V. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1330 · Cited by 72
Yun, U. J., Park, S. E., Jo, Y. S., Kim, J., & Shin, D. Y. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.04.003 · Cited by 69 · cited 2×
“IL-6/STAT-3 signalling pathway by the STAT-3 inhibitors, knockdown of gp130, or the neutralization of IL-6 impairs the growth of tumour cells exposed to DNA damage [147].”
BackgroundInhibition of JAK2 Signaling by TG101209 Enhances Radiotherapy in Lung Cancer Models
Sun, Y., Moretti, L., Giacalone, N. J., Schleicher, S. M., Speirs, C. K., Carbone, D. P., & Lü, B. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820d9d11 · Cited by 67
Siltuximab (CNTO 328): a promising option for human malignancies
Chen, B.-A., & Chen, R. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86438 · Cited by 65
Jee, S., Chiu, H., Tsai, T., Tsai, W.-E., Liao, Y., Chu, C., & Kuo, M. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.19503.x · Cited by 64
Eichten, A., Su, J., Adler, A. P., Zhang, L., Ioffe, E., Parveen, A. A., Yancopoulos, G. D., Rudge, J. S., Lowy, I., Lin, H. C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1443 · Cited by 63
Hsu, J.-H., Shi, Y., Frost, P., Yan, H., Hoang, B. Q., Sharma, S., Gera, J., & Lichtenstein, A. K. (2004) · Oncogene · doi:10.1038/sj.onc.1207459 · Cited by 62
Jiang, X., Yang, D. C., Elliott, R. L., & Head, J. F. (2011) · PubMed · Cited by 61
Ramakrishnan, V. G., Kimlinger, T. K., Haug, J. L., Timm, M., Wellik, L. E., Halling, T. M., Pardanani, A. D., Tefferi, A., Rajkumar, S. V., & Kumar, S. K. (2010) · American Journal of Hematology · doi:10.1002/ajh.21785 · Cited by 60
Ishdorj, G., Johnston, J. B., & Gibson, S. B. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0550 · Cited by 60
Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer
Nolen, B. M., Marks, J. R., Ta'san, S., Rand, A., Luong, T. M., Wang, Y., Blackwell, K., & Lokshin, A. E. (2008) · Breast Cancer Research · doi:10.1186/bcr2096 · Cited by 60
An IL-6 link between obesity and cancer
Ghosh, S. (2013) · Frontiers in Bioscience · doi:10.2741/e628 · Cited by 57
Antibody-Based Therapies in Multiple Myeloma
Tai, Y., & Anderson, K. C. (2011) · Bone Marrow Research · doi:10.1155/2011/924058 · Cited by 52
Interleukin-6 and C-Reactive Protein in Metastatic Renal Cell Carcinoma
Altundağ, Ö., Altundağ, K., & Gündüz, E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.155 · Cited by 49
Brown, C. O., Salem, K., Wagner, B. A., Bera, S., Singh, N., Tiwari, A., Choudhury, A., Buettner, G. R., & Goel, A. (2012) · Biochemical Journal · doi:10.1042/bj20112019 · Cited by 46
Stress-related hormone norepinephrine induces interleukin-6 expression in GES-1 cells
Yang, R., Lin, Q., Gao, H., & Zhang, P. (2014) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20133346 · Cited by 44
Tachibana, S., Zhang, X., Ito, K., Ota, Y., Cameron, A. M., Williams, G. M., & Sun, Z. (2014) · Cell & Bioscience · doi:10.1186/2045-3701-4-6 · Cited by 43 · cited 2×
“Thus, in PH, it appears that IL-6 facilitates the restoration of hepatic mass by activating DNA repair enzymes, followed by accurate replication in proliferating hepatic cells [151].”
BackgroundYu, X., He, L., Cao, P., & Yu, Q. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128406 · Cited by 42
Suchi, K., Fujiwara, H., Okamura, S., Okamura, H., Umehara, S., Todo, M., Furutani, A., 米田, 政., Shiozaki, A., Kubota, T., et al. (2011) · PubMed · Cited by 42
Seavey, M. M., Lu, L. D., Stump, K. L., Wallace, N. H., Hockeimer, W., O’Kane, T. M., Ruggeri, B., & Dobrzański, P. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0951 · Cited by 42
Ahmed, S. T., Mayer, A., Ji, J.-D., & Ivashkiv, L. B. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.1.154 · Cited by 41
Borhani, N., Manoochehri, M., Gargari, S. S., Novin, M. G., Mansouri, A., & Omrani, M. D. (2014) · Clinical Ovarian and Other Gynecologic Cancer · doi:10.1016/j.cogc.2014.12.004 · Cited by 38
Kurebayashi, J., Yamamoto, S., Otsuki, T., & Sonoo, H. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690099 · Cited by 38
Jäger, D., Ma, J. H., Mardiak, J., Ye, D., Korbenfeld, E. P., Zemanová, M., Ahn, H., Guo, J., Leonhartsberger, N., Stauch, K., et al. (2014) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2014.07.007 · Cited by 36
Role of Interleukin-6 in the Radiation Response of Liver Tumors
Chen, M., Hsieh, C., Chen, W., & Lai, C. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.07.2360 · Cited by 35
Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer
Kozakai, N., Kikuchi, E., Hasegawa, M., Suzuki, E., Ide, H., Miyajima, A., Horiguchi, Y., Nakashima, J., Umezawa, K., Shigematsu, N., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.321 · Cited by 34
Zoledronic acid in breast cancer: latest findings and interpretations
Gnant, M. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011420599 · Cited by 34
Kovacs, E. (2001) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(01)00079-8 · Cited by 33
Clinical Overview of Sorafenib in Breast Cancer
Moreno‐Aspitia, A. (2010) · Future Oncology · doi:10.2217/fon.10.41 · Cited by 30
Chromosomal Instability Triggered by Rrm2b Loss Leads to IL-6 Secretion and Plasmacytic Neoplasms
Chang, L., Guo, R., Huang, Q. M., & Yen, Y. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.03.040 · Cited by 29
AG490, a Jak2 inhibitor, suppressed the progression of murine ovarian cancer
Kobayashi, A., 谷崎, 優., Kimura, A., Ishida, Y., Nosaka, M., Toujima, S., Kuninaka, Y., Minami, S., Ino, K., & Kondo, T. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.09.039 · Cited by 28
Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification
Moreira, R. B., Peixoto, R. D., & Cruz, M. R. (2015) · Case Reports in Oncology · doi:10.1159/000375483 · Cited by 25
Ignatoski, K. M. W., Friedman, J. D., Escara-Wilke, J. F., Zhang, X., Daignault, S. D., Dunn, R. L., Smith, D. C., & Keller, E. T. (2008) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2008.0024 · Cited by 23
Peters, M., Solem, F. K., Goldschmidt, J., Schirmacher, P., & Rose‐John, S. (2001) · Experimental Hematology · doi:10.1016/s0301-472x(00)00650-0 · Cited by 19
Cited by
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Interleukins in cancer: from biology to therapy
Briukhovetska, D., Dörr, J., Endres, S., Libby, P., Dinarello, C. A., & Kobold, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00363-z · Cited by 781
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Hong, M., Clubb, J. D., & Chen, Y. Y. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.005 · Cited by 639
Metadata
- Authors
- Kumari, N., Dwarakanath, B. S., Das, A., & Bhatt, A. N.
- Venue
- Tumor Biology
- Published
- 2016-06-03
- Volume
- 37
- Issue
- 9
- Pages
- 11553-11572
- ISSN
- 1010-4283 (ISSN-L)
- 1423-0380
- OpenAlex
- W2409057459
- Cited by
- 1,092
- References
- 203
- FWCI
- 27.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.